These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30419425)

  • 1. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 3. Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis.
    Ganju A; Stock JC; Jordan K
    J Pharm Pract; 2023 Feb; 36(1):168-172. PubMed ID: 34169768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
    Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
    BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
    Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
    Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
    Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.
    Liou AA; Skiver BM; Yates E; Persad P; Meyer D; Farland AM; Rocco MV
    Am J Kidney Dis; 2019 May; 73(5):615-619. PubMed ID: 30528935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
    Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
    Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
    Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.